AU2022210132A1 - Anti-viral agent - Google Patents

Anti-viral agent Download PDF

Info

Publication number
AU2022210132A1
AU2022210132A1 AU2022210132A AU2022210132A AU2022210132A1 AU 2022210132 A1 AU2022210132 A1 AU 2022210132A1 AU 2022210132 A AU2022210132 A AU 2022210132A AU 2022210132 A AU2022210132 A AU 2022210132A AU 2022210132 A1 AU2022210132 A1 AU 2022210132A1
Authority
AU
Australia
Prior art keywords
strain
group
virus
antiviral agent
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022210132A
Other languages
English (en)
Inventor
Katsumi Maenaka
Akira Matsuda
Yasuko Orba
Michihito Sasaki
Hirofumi Sawa
Kentaro Uemura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Publication of AU2022210132A1 publication Critical patent/AU2022210132A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022210132A 2021-01-20 2022-01-20 Anti-viral agent Abandoned AU2022210132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-007531 2021-01-20
JP2021007531 2021-01-20
PCT/JP2022/001997 WO2022158528A1 (ja) 2021-01-20 2022-01-20 抗ウイルス剤

Publications (1)

Publication Number Publication Date
AU2022210132A1 true AU2022210132A1 (en) 2023-08-31

Family

ID=82549509

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022210132A Abandoned AU2022210132A1 (en) 2021-01-20 2022-01-20 Anti-viral agent

Country Status (8)

Country Link
US (1) US20240131046A1 (https=)
EP (1) EP4282420A4 (https=)
JP (1) JPWO2022158528A1 (https=)
KR (1) KR20230137361A (https=)
CN (1) CN116761615A (https=)
AU (1) AU2022210132A1 (https=)
CA (1) CA3206486A1 (https=)
WO (1) WO2022158528A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820248A (zh) * 2021-04-14 2024-04-05 盐野义制药株式会社 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
CA3233206A1 (en) * 2021-09-28 2023-04-06 Yuki Tachibana Pharmaceutical composition containing triazine derivative
TW202320793A (zh) * 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 含有三嗪衍生物之醫藥組合物
JP7253866B1 (ja) * 2021-11-24 2023-04-07 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024076951A2 (en) * 2022-10-04 2024-04-11 The Scripps Research Institute Antiviral prodrugs and formulations thereof
JPWO2024075794A1 (https=) * 2022-10-04 2024-04-11
CN117417387A (zh) * 2023-09-13 2024-01-19 苏州翔实医药发展有限公司 一种核苷类似物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US11738025B2 (en) * 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
MX2022012360A (es) * 2020-04-01 2022-10-21 Union Therapeutics As Tratamiento.
KR20210151949A (ko) * 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법
IL297319A (en) * 2020-04-13 2022-12-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Use of metabolic regulators for the treatment of covid-19
EP3930730A4 (en) * 2020-04-15 2022-05-11 Starpharma Pty Limited PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION
EP3912628A1 (en) * 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
US20220177982A1 (en) * 2020-12-03 2022-06-09 Regeneron Pharmaceuticals, Inc. Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用

Also Published As

Publication number Publication date
CA3206486A1 (en) 2022-07-28
KR20230137361A (ko) 2023-10-04
CN116761615A (zh) 2023-09-15
WO2022158528A1 (ja) 2022-07-28
EP4282420A1 (en) 2023-11-29
JPWO2022158528A1 (https=) 2022-07-28
EP4282420A4 (en) 2024-11-27
US20240131046A1 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
AU2022210132A1 (en) Anti-viral agent
ES2536831T3 (es) Métodos y composiciones para inhibición de polimerasa
KR102952809B1 (ko) 뉴클레오티드계 화합물의 코로나 바이러스 감염증의 치료에의 사용
KR20150093685A (ko) Hbv 어셈블리 이펙터의 대체 용도
CN115768418B (zh) 病毒抑制
JP5976224B2 (ja) ウイルス性疾患を処置するためのヘテロシクリルカルボキサミド
CN115737617A (zh) 鼠尾草酸或其衍生物在制备治疗和/或预防ⅰ型干扰素病药物中的应用
HK40104268A (en) Anti-viral agent
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
US20250009777A1 (en) Antiviral agent
JP2023072634A (ja) 抗ウイルス剤
JP2024064068A (ja) ウイルス増殖阻害剤
Islam et al. A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2
WO2022112358A2 (en) Compounds for treating enveloped virus infections
TW201629035A (zh) 抗病毒化合物、醫藥組合物及其使用方法
HK1257363B (en) Pyrrolopyrimidine derivatives for use in the inhibition of polymerase
HK1212914B (en) Pyrrolopyrimidine derivatives for use in the treatment of viral infections

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period